MYMOTE-1: Laparoscopic Myomectomy With Morcellation or Transvaginal Extraction of Surgical Specimens.

Sponsor
Università degli Studi dell'Insubria (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03570879
Collaborator
(none)
250
24

Study Details

Study Description

Brief Summary

Laparoscopic myomectomy represents the fertility-sparing gold standard approach for the management of subserosal and intramural uterine myomas: this technique allows faster recovery, less complications and improved surgical outcomes than laparotomy.

Despite these validated cornerstones of minimally invasive gynecology, the best approach for specimen retrieval is still debated. Among these approaches, surgical specimen retrieval after laparoscopic myomectomy could be performed by mini-laparotomy, by power morcellation using morcellator inserted through one of the ancillary trocars, or by transvaginal extraction through an endobag inserted at level of the posterior vaginal fornix (between the utero-sacral ligaments).

Unfortunately, mini-laparotomy has poor esthetic outcome and does not conform the current standards of minimally invasive surgery.

In addition, on 24 November 24 2014 the Food and Drug Administration updated a Safety Communication about Power Morcellation, warning against the use of laparoscopic power morcellators in the majority of women undergoing myomectomy or hysterectomy for treatment of fibroids, due to the risk of spreading an unsuspected uterine sarcoma within the abdomen and pelvis.

Considering this scenario, transvaginal extraction may represents a feasible approach for specimen retrieval. In this view, the current study aims to retrospectively compare surgical outcomes in women that underwent laparoscopic myomectomy with subsequent power morcellation (before the issuing of the abovementioned Safety Communication by the Food and Drug Administration) or transvaginal extraction (after the issuing of the abovementioned Safety Communication by the Food and Drug Administration) of the surgical specimens.

Condition or Disease Intervention/Treatment Phase
  • Device: Power morcellation
  • Procedure: Transvaginal extraction

Study Design

Study Type:
Observational
Anticipated Enrollment :
250 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Analysis of Surgical Outcomes in Women Undergoing Laparoscopic Myomectomy With Morcellation or Transvaginal Extraction of Surgical Specimens
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Power morcellation

Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.

Device: Power morcellation
Power morcellation of surgical specimens after laparoscopic myomectomy.

Transvaginal extraction

Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.

Procedure: Transvaginal extraction
Transvaginal extraction of surgical specimens after laparoscopic myomectomy.

Outcome Measures

Primary Outcome Measures

  1. Complication rate [Within 12 months after surgery.]

    Number of surgical complications (Clavien-Dindo Classification)

Secondary Outcome Measures

  1. Operative time [Through study completion, an average of 10 years (retrospective analysis)]

    Duration of the surgery, expressed in minutes.

  2. Blood loss [Through study completion, an average of 10 years (retrospective analysis)]

    Blood loss during the surgery, expressed in milliliters (ml).

  3. Hospital stay [Through study completion, an average of 10 years (retrospective analysis)]

    Duration of the hospitalization, expressed in days

  4. Sexual function [6 and 12 months after surgery.]

    Sexual function evaluated by Female Sexual Function Index questionnaire, investigating quantity and quality of sex [scale total score minimum: 2 (worse outcome), maximum: 36 (best outcome)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women affected by single or multiple uterine myomas.

  • Signed informed consent.

Exclusion Criteria:
  • Human papilloma virus-related pathologies at pap-smear within the 12 months preceding surgery.

  • Women with obliteration of the cul-de-sac.

  • Women with the suspected cancer of gynecological origin.

  • Women who had never experienced complete sexual intercourse before the operation.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Università degli Studi dell'Insubria

Investigators

  • Principal Investigator: Antonio Simone Laganà, M.D., Università degli Studi dell'Insubria
  • Principal Investigator: Jvan Casarin, M.D., Università degli Studi dell'Insubria
  • Study Chair: Antonella Cromi, M.D., Ph.D., Università degli Studi dell'Insubria
  • Study Director: Fabio Ghezzi, M.D., Università degli Studi dell'Insubria

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antonio Simone Laganà, Principal Investigator, Università degli Studi dell'Insubria
ClinicalTrials.gov Identifier:
NCT03570879
Other Study ID Numbers:
  • MYMOTE-1
First Posted:
Jun 27, 2018
Last Update Posted:
Sep 30, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Antonio Simone Laganà, Principal Investigator, Università degli Studi dell'Insubria
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 30, 2021